Locally Delivered Aloe Vera Gel in the Treatment of Chronic Periodontitis Patients With Diabetes Mellitus

Local Drug Delivery of Aloe Vera Gel in Chronic Periodontitis Patients With Controlled Diabetes Mellitus

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02437747

Enrollment

Registered

2015-05-08

Start date

2014-06-30

Completion date

2015-03-31

Last updated

2015-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Chronic Periodontitis

Keywords

clinical trial

Brief summary

A study on the effect of locally delivered aloe vera gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis patients with controlled type II diabetes mellitus.The evaluation of Plaque Index, Gingival Index, Probing Pocket Depth, Relative Attachment Level at baseline, 6 weeks and 3 months and Glycosylated heamoglobin at baseline and 3 months.

Detailed description

Aloe vera gel was locally delivered in the periodontal pockets of ≥ 5mm bilaterally in chronic periodontitis patients with diabetes under control.(HbA1c-6.6-8.6%).The study design had two groups-one in which scaling and root planing and local delivery of aloe vera gel and the other only scaling and root planing. The evaluation of clinical parameters of PI, GI, PPD and RAL at baseline, 6 weeks and 3 months. HbA1c evaluated at baseline and 3 months.

Interventions

DRUGSRP + Aloe

Scaling and root planing along with aloe vera application was done

PROCEDURESRP

Scaling and root planing was done

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 55 Years

Healthy volunteers

Inclusion criteria

1. Patients age 30 - 55 years from both genders. 2. Patients with controlled Type II Diabetes Mellitus (HbA1c \< 7%) with Chronic periodontitis having ≥ 5mm periodontal pockets bilaterally atleast in one site. 3. Patients on oral hypoglycaemic agents. 4. Subjects who have not received periodontal therapy within preceding 6 months. 5. Patients willing to comply with all study related procedures.

Exclusion criteria

1. Subjects who have received antibiotic treatment in the preceding 3 months. 2. History of prolonged use of antibiotics/ steroids/ immunosuppressive agents /aspirin/ anticoagulants/ other medications including any other herbal products. 3. Pregnant or lactating women. 4. Smokers. 5. History of systemic diseases like hypertension, HIV, bone metabolic disorders, radiation therapy, Osteoporosis, immunosuppressive therapy, cancer etc.other than Diabetes. 6. Unwilling patients

Design outcomes

Primary

Measure	Time frame	Description
Clinical parameter of probing pocket depth	3 months	Clinically change in the probing pocket depth.

Secondary

Measure	Time frame	Description
Glycosylated haemoglobin	3 months	HbA1c levels evaluated at baseline and 3 months
Clinical parameter of plaque index	3 months	Change in the plaque index.
Clinical parameter of gingival index	3 months	Change in the gingival index.
Clinical parameter of relative attachment level	3 months	Change in the relative attachment level.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026